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The nephrotic syndrome represents one of the 
major clinical problems in nephrology. It is usually 
defined as the constellation of clinical findings which 
includes edema, massive proteinuria, low serum albu-
min, high serum cholesterol, and the presence of oval 
fat bodies in the urine.1 However, if we focus on the 
primary disturbance in the patient, that is, massive 
proteinuria, the nephrotic syndrome may be defined 
more simply as the clinical and metabolic con-
sequences of persistent and massive proteinuria. The 
other manifestations listed in the classic definition are 
all inconstant and secondary to this loss of protein 
and may be found in other clinical disorders. Protein-
uria is considered massive when it is greater than 3 .5 
mg/ kg body weight per day, and persistent when 
present for many weeks or months. For diagnosis of 
the nephrotic syndrome, 24-hour urine protein excre-
tion must be measured; a spot measurement is in-
adequate because some patients with massive pro-
teinuria produce occasional specimens with little or 
no protein. 
In understanding potential causes of the neph-
rotic syndrome, it is useful to recognize two general 
categories of disease.2 •3 One is the nephrotic syn-
drome associated with systemic illnesses. The other is 
not associated with a recognizable systemic process, 
and thus reflects only intrinsic renal disease. The 
most common systemic diseases associated with the 
nephrotic syndrome are diabetes mellitus, systemic 
lupus erythematosus, malignancy and amyloidosis. 
Additionally, there is a large variety of other diseases 
less commonly associated with the nephrotic syn-
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drome. Many of these involve immune and toxic 
reactions related to drugs, as well as infectious and 
environmental agents. Although these entities are un-
common, it is important to recognize them, as re-
moval of the dn1g or toxin, or definitive treatment of 
the infection, is a fundamental part of the manage-
ment of these patients. Drugs shown to be associated 
with the nephrotic syndrome include the antiepileptic 
drugs paradione and tridione, anticoagulant agents, 
and penicillin. Forms of allergic reactions associated 
with the nephrotic syndrome include those following 
bee sting or exposure to poison oak or poison ivy. 
Chronic infections which are known to be com-
plicated by the nephrotic syndrome include syphilis, 
malaria, hepatitis and toxoplasmosis. 
There are several intrinsic renal diseases which 
cause the nephrotic syndrome. Recognition of these 
depends on characteristic morphologic findings in the 
renal biopsy specimen. The first is the clini-
copathologic entity referred to as nil disease or lipoid 
nephrosis .2 As implied in the term nil disease, there is 
little, if any, change in the normal architecture of the 
kidney when examined by light microscopy; however, 
electron microscopy does disclose changes of epithe-
lial foot process fusion. Nil disease is the pre-
dominant cause of the nephrotic syndrome in chil-
dren, particularly between ages 2 and 5 years; it is a 
less common cause in adults, accounting for approxi-
mately 15% of adult cases of primary nephrotic syn-
drome. 
The second intrinsic renal disease which causes 
the nephrotic syndrome is a condition termed idiopa-
thic membranous glomerulopathy2 and it is found 
most frequently in adults. This term refers to the 
morphological changes of diffuse thickening of the 
basement membrane of all glomeruli. Within and to 
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the outside of the basement membrane are found 
desposits which have been shown to contain immu-
noglobulins and serum complement components. 
They are thought to result from the deposition of 
circulating complexes of antigen and antibody, and 
are responsible for injury to the glomerulus which 
results in heavy proteinuria. Membranous glomeru-
lopathy accounts for approximately 40% of the pri-
mary nephrotic syndrome in adults . It is relatively 
uncommon in children in the United States. 
A third intrinsic renal disease which causes 
nephrotic syndrome is termed membranoprolifera-
tive glomerulonephritis.3 In this disease the mesangial 
or supporting cell of the glomerulus is affected. Al-
though the cause of this disease is not understood, 
immune deposits may be found in the mesangial area. 
This is an uncommon cause ofnephrotic syndrome in 
adults but is perhaps the most common cause in 
patients aged IO to 20 years. Prognosis for this dis-
ease is not good as its course commonly leads to 
renal failure. 
The fourth intrinsic disease recognized as caus-
ing the nephrotic syndrome is termed focal sclerosing 
glomerulonephritis.2•3 As this pathologic term in-
dicates, the lesion involves a process which at first is 
confined only to parts of individual glomeruli. Again, 
the cause is unknown, although immune deposits are 
found in the areas of scarring. Like membranoprolif-
erative glomerulonephritis, this disease also fre-
quently results in renal failure. 
In managing patients with the nephrotic syn-
drome, it is useful to bear in mind the patho-
physiology of the syndrome. Although the most fre-
quent concern is with the development of massive 
edema, it should be remembered that such edema is a 
consequence of massive loss of protein into the urine. 
This in turn leads to depletion of intra vascular albu-
min and reduction of plasma oncotic pressure. In 
turn, fluid escapes from the vascular compartment 
into the interstitial tissue. As a compensatory re-
sponse to the fall in plasma volume, there is de-
creased salt and water excretion by the kidney which 
may further increase the accumulation of edema. If 
intravascular albumin depletion can be prevented or 
reversed, significant problems with edema and fluid 
retention will not develop. As albumin depletion is 
caused primarily by loss through a leaky glomerulus, 
the first approach, if possible, should be to reverse the 
albumin leak. As we shall see later, this is regularly 
accomplished only in nil disease in which the leak is 
predictably corrected by steroids. In other conditions 
in which the albumin leak is not remedial, metabolic 
considerations should be first and foremost in man-
agement. A high-protein and high-caloric diet can 
result in significant repletion of intravascular albu-
min.5 To the extent that albumin loss can not be 
matched by increased dietary protein, then salt re-
striction and diuretics may be necessary to prevent 
undue accumulation of edema. From a practical 
standpoint, the diet of the nonazotemic patient 
should contain a minimum of 100 gm of high-quality 
protein and approximately 3,500 calories for the av-
erage nephrotic adult. At times, protein intake of 2-3 
gm/kg of body weight will be required. Since many of 
these patients are anorectic and have been grossly 
malnourished for some time, the diet may have to be 
increased gradually until these goals are accom-
plished. This will require persistent and close cooper-
ation between the patient, the physician, and the 
dietitian . 
If serum albumin remains severely depressed de-
spite optimal intake of protein, it is probable that salt 
and water restriction, as well as diuretics, may be 
necessary for control of severe edema. One must re-
member that, although there may be massive accu-
mulation of edema, there is at the same time potential 
for significant intravascular volume depletion. Ther-
apy designed to reduce edema accumulation may fur-
ther reduce intravascular volume, and potentially re-
sult in shock. Judicious use of salt restriction and 
diuretics is necessary in order to achieve the appro-
priate balance in which severe accumulation of 
edema is prevented without unduly jeopardizing in-
travascular volume. In general, this involves sodium 
restriction of approximately 40-60 mEq/p day. Di-
uretics should be adjusted so that edema is not re-
duced to the point where postural changes in blood 
pressure and pulse occur. Although this may involve 
some trial and error, one can usually arrive at a body 
weight in which massive edema is prevented but not 
at the expense of severe volume depletion. 
The nephrotic syndrome may also be com-
plicated by increased susceptibility to infection. Prior 
to the introduction of steroid and antibiotic therapy, 
pneumococcal pneumonia and/or peritonitis was a 
major cause of death in nephrotic children. This is at 
least in part because of loss of immunoglobulins in the 
urine. In addition, protein malnutrition and edema-
tous tissue may contribute to reduced host defenses. 
It is not always possible to prevent the loss of immu-
noglobulins in the urine of patients with persistent, 
heavy proteinuria, but massive edema and malnutri-
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tion are potentially correctable. It is most important 
that the physician be alert to early signs of infection 
in these patients so that they are treated definitively 
and aggressively. 
An increased thromboembolic tendency is an 
additional potential complication of the nephrotic 
syndrome. Although the mechanism is not clearly 
understood, there are data to suggest that a hyper-
coagulable state may exist in association with the 
nephrotic syndrome. Care should be taken that other 
factors, such as venous stasis, which predispose to 
thromboembolism, be avoided in order to minimize 
this risk. It is also important that those providing 
medical care for these patients be especially attuned 
to this problem, so that definitive diagnosis and treat-
ment may be accomplished at the earliest possible 
time. There appears to be no basis for use of anti-
coagulant agents except in documented episodes of 
pulmonary embolus. For unclear reasons, there 
seems to be a predilection for the formation of clots 
within the venous system of the nephrotic kidney. 
Again, it appears that anticoagulants are not in-
dicated except in the occurrence of a pulmonary em-
bolus. 
It has been conclusively demonstrated that pa-
tients with long-standing nephrotic syndrome may 
develop accelerated atherosclerotic disease, leading 
to an increased risk of coronary artery disease and 
acute myocardial infarction; this appears to be re-
lated to prolonged hyperlipidemia. There is an in-
verse relationship between serum albumin and serum 
lipid levels. Any maneuver which improves the serum 
albumin level, such as correction of protein malnutri-
tion, can be expected also to lower serum lipid levels. 
Treatment with clofibrate does not appear to be 
highly effective in treating hyperlipidemia associated 
with the nephrotic syndrome and may be associated 
with severe side effects if the dosage is not reduced to 
correspond to the reduced serum albumin levels. 
The most fundamental concern in management 
of the nephrotic syndrome should be the correction 
of increased glomerular protein leakage. If protein 
loss can be reversed, all secondary problems will re-
solve. Two general considerations relate to abnormal 
protein leakage. First, the physician should be aware 
that the nephrotic syndrome could be a manifestation 
of some reversible systemic process. Any drug, toxin, 
or allergen which could potentially cause the neph-
rotic syndrome should be removed, if possible. Sys-
temic diseases associated with the nephrotic syn-
drome, such as malignancy and chronic infections, 
should be identified and treated definitively. Even 
when malignancy is not curable, reduction in tumor 
mass may lead to resolution of the nephrotic syn-
drome. 
The second approach to treatment of glomerular 
protein leakage involves the use of steroids and im-
munosuppressant agents. It has been shown conclu-
sively in only one disease, nil disease, that these 
agents can predictably reverse glomerular leakage of 
protein; for the rest there is little evidence of efficacy 
of such agents. In nil disease, treatment with predni-
sone, in doses of 40-60 mg/day/m2 body surface area 
in children and 1 mg/day/kg body weight in adults, 
will result in a significant reduction in the level of 
proteinuria within 7 to 28 days. In general, children 
will respond quickly, and their proteinuria will fall 
off rapidly to undetectable levels. Adults tend to re-
spond more slowly and less completely but will usu-
ally have less than l gm of protein excretion per day 
within the first 28 days of treatment. After clearing or 
significant reduction in the level of proteinuria, treat-
ment is usually switched to an alternate-day regimen 
and the steroids reduced and subsequently discontin-
ued over the next two to three months. Immuno-
suppressant agents, such as cyclophosphamide, may 
be useful in some patients with nil disease who have 
frequent relapses upon cessation of steroid therapy. 
Recent evidence suggests that these agents may pre-
vent or reduce the frequency of such relapses. 
In addition to the beneficial effect of steroids and 
immunosuppressant agents on the proteinuria of nil 
disease, there is also a recent and ongoing interest as 
to whether these agents may prevent or slow the rate 
of progression of renal failure in glomerulonephritis 
associated with the nephrotic syndrome. The severe 
glomerulonephritis of systemic lupus erythematosus, 
as well as idiopathic membranous and membrano-
proliferative glomerulonephritis, are diseases whose 
prognosis may be improved by these agents; however, 
studies supporting such conclusions have not been 
adequately controlled and remain controversial. 
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